CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 32 filers reported holding CATABASIS PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $72,000 | -17.2% | 90,300 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $87,000 | -46.3% | 90,300 | -10.9% | 0.00% | -50.0% |
| Q1 2017 | $162,000 | -55.7% | 101,347 | 0.0% | 0.00% | -60.0% |
| Q4 2016 | $366,000 | +15.8% | 101,347 | +97.4% | 0.01% | 0.0% |
| Q3 2016 | $316,000 | +209.8% | 51,347 | +85.4% | 0.01% | +150.0% |
| Q2 2016 | $102,000 | – | 27,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $23,118,000 | 12.93% |
| Clarus Ventures, LLC | 2,752,488 | $22,268,000 | 12.81% |
| Camber Capital Management LP | 1,000,000 | $8,090,000 | 0.69% |
| Rhenman & Partners Asset Management AB | 300,427 | $2,430,000 | 0.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 327,476 | $2,595,000 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 628,482 | $5,084,000 | 0.20% |
| Spark Investment Management LLC | 32,500 | $263,000 | 0.03% |
| Tower Research Capital LLC (TRC) | 10,764 | $87,000 | 0.01% |
| VANGUARD GROUP INC | 4,732,472 | $168,937,000 | 0.01% |
| Alyeska Investment Group, L.P. | 40,220 | $325,000 | 0.00% |